Ohr Pharmaceutical Inc. (OHRP) Downgraded by Zacks Investment Research to “Hold”
According to Zacks, “Ohr Pharmaceutical, Inc. is a pharmaceutical company. It is focused on the development of novel therapeutics for the treatment of cancer cachexia, wet form of age-related macular degeneration and ophthalmic neovascularization disorders. Ohr Pharmaceutical, Inc. is headquartered in New York. “
OHRP has been the topic of several other reports. Roth Capital reiterated a buy rating and issued a $13.00 price objective on shares of Ohr Pharmaceutical in a report on Thursday, June 16th. Brean Capital assumed coverage on shares of Ohr Pharmaceutical in a report on Tuesday. They issued a hold rating on the stock.
Shares of Ohr Pharmaceutical (NASDAQ:OHRP) traded down 0.71% during trading on Wednesday, reaching $2.78. 35,621 shares of the company traded hands. Ohr Pharmaceutical has a 12 month low of $2.44 and a 12 month high of $6.56. The stock’s market capitalization is $89.25 million. The company has a 50-day moving average of $2.74 and a 200-day moving average of $2.93.
Ohr Pharmaceutical (NASDAQ:OHRP) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.24) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.03. Analysts forecast that Ohr Pharmaceutical will post ($0.94) earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in OHRP. Geode Capital Management LLC increased its position in Ohr Pharmaceutical by 3.9% in the first quarter. Geode Capital Management LLC now owns 152,915 shares of the company’s stock valued at $490,000 after buying an additional 5,794 shares during the period. Opaleye Management Inc. acquired a new position in Ohr Pharmaceutical during the first quarter valued at approximately $1,175,000. GSA Capital Partners LLP acquired a new position in Ohr Pharmaceutical during the second quarter valued at approximately $144,000. BlackRock Fund Advisors increased its position in Ohr Pharmaceutical by 14.8% in the second quarter. BlackRock Fund Advisors now owns 75,333 shares of the company’s stock valued at $206,000 after buying an additional 9,685 shares during the period. Finally, Vanguard Group Inc. increased its position in Ohr Pharmaceutical by 1.1% in the second quarter. Vanguard Group Inc. now owns 922,616 shares of the company’s stock valued at $2,528,000 after buying an additional 9,763 shares during the period. Institutional investors and hedge funds own 11.32% of the company’s stock.
Receive News & Stock Ratings for Ohr Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.